Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Geriatric Psychiatry"
DOI: 10.1002/gps.5789
Abstract: Aducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia.… read more here.
Keywords: cognitive service; eligibility aducanumab; cerebrospinal fluid; use criteria ... See more keywords